3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Breast Neoplasms
45
Sarcoma
33
Lymphoma, Large B-Cell, Diffuse
32
Neoplasms
25
Lymphoma
20
Lymphoma, Non-Hodgkin
19
Ovarian Neoplasms
17
Lymphoma, Follicular
16
Neoplasm Metastasis
12
Triple Negative Breast Neoplasms
11
Lymphoma, B-Cell
11
Endometrial Neoplasms
11
Recurrence
10
Carcinoma, Hepatocellular
8
Hodgkin Disease
7
Lymphoma, T-Cell, Peripheral
6
Hematologic Diseases
6
Sarcoma, Kaposi
5
Lymphoma, Mantle-Cell
5
Leiomyosarcoma
5
HIV Infections
5
Acquired Immunodeficiency Syndrome
5
Multiple Myeloma
4
Liposarcoma
4
Small Cell Lung Carcinoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Lymphoma, B-Cell, Marginal Zone
3
Liver Neoplasms
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Fallopian Tube Neoplasms
3
Interventions
ofatumumab
10
ibrutinib
6
Rituximab
5
acalabrutinib
4
Cyclophosphamide
3
spebrutinib
2
pirtobrutinib
2
obinutuzumab
2
navitoclax
2
fludarabine phosphate
2
Tablets
2
Lenalidomide
2
KW-2478
2
Chlorambucil
2
Antigens, CD19
2
ARQ531
2
venetoclax
1
tirabrutinib
1
pomalidomide
1
pivalyloxymethyl butyrate
1
immunotoxin HA22
1
idelalisib
1
idecabtagene vicleucel
1
fludarabine
1
dinaciclib
1
bempegaldesleukin
1
Vincristine
1
Rabeprazole
1
Prednisone
1
Observation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leukemia, B-Cell
×
Doxorubicin
×
Clear all
NCT06564038
2026-05-14
Soundtrack-E
AstraZeneca
Phase 1/2
Recruiting
408 enrolled